High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

被引：0

作者：

F Zagouri

Z Bago-Horvath

F Rössler

A Brandstetter

R Bartsch

C A Papadimitriou

C Dimitrakakis

A Tsigginou

I Papaspyrou

A Giannos

M-A Dimopoulos

M Filipits

机构：

[1] Institute of Cancer Research,Department of Medicine I

[2] Comprehensive Cancer Center,Department of Pathology

[3] Medical University of Vienna,Division of Oncology, Department of Medicine I

[4] Comprehensive Cancer Center,Department of Clinical Therapeutics

[5] Medical University of Vienna,Department of Obstetrics and Gynaecology

[6] Comprehensive Cancer Center,Department of Pathology

[7] Medical University of Vienna,undefined

[8] Alexandra Hospital,undefined

[9] Medical School,undefined

[10] University of Athens,undefined

[11] Alexandra Hospital,undefined

[12] Medical School,undefined

[13] University of Athens,undefined

[14] Alexandra Hospital,undefined

[15] Medical School,undefined

[16] University of Athens,undefined

来源：

British Journal of Cancer | 2013年 / 108卷

关键词：

biomarkers; prognosis; MET; triple-negative breast cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1100 / 1105

页数：5

共 50 条

[1] High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
Zagouri, F.
Bago-Horvath, Z.
Roessler, F.
Brandstetter, A.
Bartsch, R.
Papadimitriou, C. A.
Dimitrakakis, C.
Tsigginou, A.
Papaspyrou, I.
Giannos, A.
Dimopoulos, M-A
Filipits, M.
BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1100 - 1105
[2] Comment on 'High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer'
Ho-Yen, C.
Bowen, R. L.
Kermorgant, S.
Jones, J. L.
BRITISH JOURNAL OF CANCER, 2013, 108 (10) : 2195 - 2196
[3] Comment on ‘High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer’
C Ho-Yen
R L Bowen
S Kermorgant
J L Jones
British Journal of Cancer, 2013, 108 : 2195 - 2196
[4] Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?
Schmidt, Gilda
Solomayer, Erich-Franz
Bohle, Rainer Maria
Gerlinger, Christoph
Radosa, Julia Caroline
Endrikat, Jan
Kasoha, Mariz
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (08) : 2109 - 2116
[5] Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?
Gilda Schmidt
Erich-Franz Solomayer
Rainer Maria Bohle
Christoph Gerlinger
Julia Caroline Radosa
Jan Endrikat
Mariz Kasoha
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 2109 - 2116
[6] Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer
Choi, Y. S.
RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S709 - S710
[7] Vimentin as a poor prognostic factor for triple-negative breast cancer
Nami Yamashita
Eriko Tokunaga
Hiroyuki Kitao
Yuichi Hisamatsu
Kenji Taketani
Sayuri Akiyoshi
Satoko Okada
Shinichi Aishima
Masaru Morita
Yoshihiko Maehara
Journal of Cancer Research and Clinical Oncology, 2013, 139 : 739 - 746
[8] Survivin Is a Poor Prognostic Factor in Triple-Negative Breast Cancer
Thrashvili, Gulisa
Ghaffari, Abdi
Sun, Xiaoqun
Day, Andrew
Boudreau, Lee
Raptis, Leda
Madarnas, Yolanda
Elliott, Bruce
SenGupta, Sandip
LABORATORY INVESTIGATION, 2015, 95 : 71A - 71A
[9] Survivin Is a Poor Prognostic Factor in Triple-Negative Breast Cancer
Turashvili, Gulisa
Ghaffari, Abdi
Sun, Xiaoqun
Day, Andrew
Boudreau, Lee
Raptis, Leda
Madarnas, Yolanda
Elliott, Bruce
SenGupta, Sandip
MODERN PATHOLOGY, 2015, 28 : 71A - 71A
[10] Vimentin as a poor prognostic factor for triple-negative breast cancer
Yamashita, Nami
Tokunaga, Eriko
Kitao, Hiroyuki
Hisamatsu, Yuichi
Taketani, Kenji
Akiyoshi, Sayuri
Okada, Satoko
Aishima, Shinichi
Morita, Masaru
Maehara, Yoshihiko
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (05) : 739 - 746

← 1 2 3 4 5 →